Anatolia Biyoteknoloji (ANGEN) Fundamental Analysis
This page summarises the financial statements and the KapAI scorecard of Anatolia Biyoteknoloji (ANGEN) in the İlaç ve Sağlık sector for the 2026/6 period. Figures are compiled from the company’s reported balance sheet and income statement, in millions of Turkish lira.
Company Information
- Company: Anatolia Biyoteknoloji
- Ticker: ANGEN
- Sector: İlaç ve Sağlık
- Latest reporting period: 2026/6
KapAI Scorecard
Overall score: 2.9 / 5
- Profitability: 3.2 / 5
- Liquidity: 2.9 / 5
- Leverage: 3.0 / 5
- Efficiency: 2.5 / 5
Summary Income Statement (TRY million)
Period: 2026/6 · Compared with: 2025/6
| Item | 2026/6 | 2025/6 | Change |
|---|---|---|---|
| Revenue | 412 | 404 | +1.9% |
| Gross Profit | 229 | 258 | -11.0% |
| Operating Profit | -49 | 9 | -620.4% |
| EBITDA | 0 | 0 | — |
| Net Monetary Position Gains | -96 | -248 | +61.4% |
| Net Profit for the Period | -213 | -267 | +20.3% |
Summary Balance Sheet (TRY million)
Period: 2026/6 · Compared with: 2025/6
| Item | 2026/6 | 2025/6 | Change |
|---|---|---|---|
| Current Assets | 722 | 734 | -1.7% |
| Non-Current Assets | 1,996 | 1,250 | +59.7% |
| Total Assets | 2,717 | 1,984 | +37.0% |
| Current Liabilities | 357 | 166 | +114.7% |
| Non-Current Liabilities | 555 | 177 | +213.8% |
| Total Liabilities | 912 | 343 | +165.7% |